TTM
−$18.95M
YoY change
+194.4%
5Y CAGR
—
Peak year (2017)
−$1.88M
Cumulative EBITDA
−$212.98M
EBITDA history chart for Equillium (EQ) from 2017 to 2025
Latest: −$22.28M
EBITDA growth chart for Equillium (EQ) from 2017 to 2025
Latest: +194.4%
EBITDA history table for Equillium (EQ) from 2017 to 2025
| 2025 | −$22.28M | +194.4% | −$14.71M | ||
| 2024 | −$7.57M | -37.6% | +$4.57M | ||
| 2023 | −$12.14M | -80.2% | +$49.12M | ||
| 2022 | −$61.26M | +61.6% | −$23.35M | ||
| 2021 | −$37.91M | +32.2% | −$9.24M | ||
| 2020 | −$28.67M | +13.3% | −$3.37M | ||
| 2019 | −$25.30M | +136.7% | −$14.61M | ||
| 2018 | −$10.69M | +467.7% | −$8.80M | ||
| 2017 | −$1.88M | — | — |
- 2025−$22.28M+194.4%
- 2024−$7.57M-37.6%
- 2023−$12.14M-80.2%
- 2022−$61.26M+61.6%
- 2021−$37.91M+32.2%
- 2020−$28.67M+13.3%
- 2019−$25.30M+136.7%
- 2018−$10.69M+467.7%
- 2017−$1.88M—
EBITDA values are taken from Equillium's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Equillium (EQ)
According to Equillium's latest reported financial statements, the company's current EBITDA (TTM) is −$18.95M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Equillium (EQ) most recent annual EBITDA stands at −$22.28M (2025) – surged 194.4% year-over-year.
−$1.88M stands as the all-time-high annual EBITDA, posted in 2017, against a low of −$61.26M during 2022.
Equillium EBITDA by Year
Equillium EBITDA 2025: −$22.28M
2025's EBITDA for Equillium came in at −$22.28M, surged 194.4% from 2024.
Equillium EBITDA 2024: −$7.57M
Equillium posted EBITDA of −$7.57M in 2024, plunged 37.6% below 2023.
Equillium EBITDA 2023: −$12.14M
In 2023, Equillium reported EBITDA of −$12.14M, plunged 80.2% below 2022.
Equillium EBITDA 2022: −$61.26M
Equillium EBITDA in 2022 was −$61.26M, surged 61.6% from 2021. This figure represents the lowest annual value in the available history.
Equillium EBITDA 2021: −$37.91M
Equillium EBITDA in 2021 was −$37.91M.
See more financial history for Equillium (EQ).
Sector peers by EBITDA
Healthcare peers of Equillium (EQ), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Equillium (EQ) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation